Pálsson, R. & Patel, U. D. Cardiovascular complications of diabetic kidney disease. Adv. Chronic. Kidney Dis. 21(3), 273–280 (2014).
Lawes, C. M., Vander Hoorn, S. & Rodgers, A. Hypertension ISO. Global burden of blood-pressure-related disease, 2001. Lancet. 371(9623), 1513–1518 (2008).
Patney, V., Whaley-Connell, A. & Bakris, G. Hypertension management in diabetic kidney disease. Diabetes Spectr. 28(3), 175–180 (2015).
Ohishi, M. Hypertension with diabetes mellitus: Physiology and pathology. Hypertens Res. 41(6), 389–393 (2018).
Vallon, V., Blantz, R. & Thomson, S. The salt paradox and its possible implications in managing hypertensive diabetic patients. Curr. Hypertens Rep. 7(2), 141–147 (2005).
Navar, L. G. The role of the kidneys in hypertension. J. Clin. Hypertens. 7(9), 542–549 (2005).
Ismail, N., Becker, B., Strzelczyk, P. & Ritz, E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int. 55(1), 1–28 (1999).
Goud, A., Zhong, J., Peters, M., Brook, R. D. & Rajagopalan, S. GLP-1 agonists and blood pressure: A review of the evidence. Curr. Hypertens. Rep. 18(2), 16 (2016).
Wajdlich, M. & Nowicki, M. Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease. J. Physiol. Pharmacol. 72(5), 751–761 (2021).
Katout, M. et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression. Am. J. Hypertens. 27(1), 130–139 (2014).
Jacobsen, L. V., Flint, A., Olsen, A. K. & Ingwersen, S. H. Liraglutide in type 2 diabetes mellitus: Clinical pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 55(6), 657–672 (2016).
Jacobsen, L. V., Hindsberger, C., Robson, R. & Zdravkovic, M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898–905 (2009).
Wang, B. et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials. Diabetes Obes. Metab. 15(8), 737–749 (2013).
Saraiva, F. K. & Sposito, A. C. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc. Diabetol. 13, 142 (2014).
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S. & O’Hare, J. P. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 3(1), e001986 (2013).
Sun, F. et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res. Clin. Pract. 110(1), 26–37 (2015).
Davies, M. J. et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. Diabetes Care. 39(2), 222–230 (2016).
Hiramatsu, T., Ozeki, A., Ishikawa, H. & Furuta, S. Long term effects of Liraglutide in Japanese patients with type 2 diabetes among the subgroups with different renal functions: Results of 2-year prospective study. Drug Res. 67(11), 640–646 (2017).
Hiramatsu, T. et al. Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis. Ther. Apher. Dial. 19(6), 598–605 (2015).
Idorn, T. et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, placebo-controlled, double-blind, parallel-group. Randomized Trial. Diabetes Care. 39(2), 206–213 (2016).
Kumarathurai, P. et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: A randomized, double-blind, placebo-controlled, crossover study. J. Hypertens. 35(5), 1070–1078 (2017).
Lovshin, J. A. et al. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 38(1), 132–139 (2015).
Liakos, A. et al. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabet. Obes. Metab. 21(3), 517–524 (2018).
Bharucha, A. E. et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295(3), R874–R880 (2008).
Asmar, A. et al. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am. J. Physiol. Endocrinol. Metab. 308(8), E641–E649 (2015).
Mendis, B., Simpson, E., MacDonald, I. & Mansell, P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br. J. Clin. Pharmacol. 74(3), 437–444 (2012).
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F. & Rossing, P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet. Med. 32(3), 343–352 (2015).
Skov, J. et al. Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 98(4), E664–E671 (2013).
Gutzwiller, J. P. et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89(6), 3055–3061 (2004).
Muskiet, M. H. et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabet. Obes. Metab. 18(2), 178–185 (2016).
Tonneijck, L. et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: A randomised, double-blind, placebo-controlled trial. Diabetologia. 59(7), 1412–1421 (2016).
Skov, J. et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: A randomized clinical trial. Diabet. Obes. Metab. 18(6), 581–589 (2016).
Hewitson, T. D., Holt, S. G. & Smith, E. R. Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype—Role of risk factors and epigenetics. Front. Pharmacol. 8, 520 (2017).
Hung, S. C. et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int. 85(3), 703–709 (2014).
Baretić, M., Kušec, V. & Pavlić-Renar, I. Glucagon-Like peptide-1 infusion suppresses aldosterone levels in healthy normal-weight individuals: Double-blind, placebo-controlled crossover study. Diabet. Ther. 9, 2315–2324 (2018).
Sedman, T., Heinla, K., Vasar, E. & Volke, V. Liraglutide treatment may affect renin and aldosterone release. Horm. Metab. Res. 49(1), 5–9 (2017).
Asmar, A. et al. Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: A functional GLP-1-renal axis in man. J. Clin. Endocrinol. Metab. 104(7), 2509–2519 (2019).
Asmar, A. et al. The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor. J. Clin. Endocrinol. Metab. 106(1), e11–e19 (2021).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41598-024-55724-z